Trials / Completed
CompletedNCT05394493
An Observational Chart Review Study To Describe The Real-World Outcomes And Use Of Avelumab In Combination With Axitinib For Treatment Of Patients With aRCC In The UK
An Observational Chart Review Study to Describe the Real-world Outcomes and Use of Avelumab in Combination With Axitinib for Treatment of Patients With Advanced Renal Cell Carcinoma in the United Kingdom.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 130 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
An observational chart review study to describe the real-world outcomes and use of avelumab in combination with axitinib for treatment of patients with advanced renal cell carcinoma in the United Kingdom.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | avelumab | as provided in real world setting |
| DRUG | axitinib | as provided in real world settings |
Timeline
- Start date
- 2021-06-11
- Primary completion
- 2023-08-30
- Completion
- 2023-08-30
- First posted
- 2022-05-27
- Last updated
- 2023-12-06
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT05394493. Inclusion in this directory is not an endorsement.